Limits...
Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review.

Deandrea S, Corli O, Moschetti I, Apolone G - Ther Clin Risk Manag (2009)

Bottom Line: Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids.To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies.A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration.

View Article: PubMed Central - PubMed

Affiliation: Center for the Evaluation and Research on Pain (CERP), Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

ABSTRACT
Pain is a frequent and important symptom in cancer patients. Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids. To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies. We identified 19 eligible papers describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective studies), including a total of about 5000 cancer patients. Given the poor quality of reports and the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was not appropriate for combining the results statistically. A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative appraisal of each study suggests a positive risk benefit profile, well designed and statistically powered controlled clinical trials are needed to confirm this preliminary evidence.

No MeSH data available.


Related in: MedlinePlus

Flowchart of manuscript selection.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2747389&req=5

f1-tcrm-5-707: Flowchart of manuscript selection.

Mentions: The search of MEDLINE and EMBASE with the review of titles and abstracts, integrated by scanning the references and consulting experts in the field, yielded 27 relevant articles. Four articles were excluded because they were published as abstracts and/or full text was not available, and the other four were excluded because they were written in languages other than English. Figure 1 presents a flowchart of manuscript selection.


Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review.

Deandrea S, Corli O, Moschetti I, Apolone G - Ther Clin Risk Manag (2009)

Flowchart of manuscript selection.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2747389&req=5

f1-tcrm-5-707: Flowchart of manuscript selection.
Mentions: The search of MEDLINE and EMBASE with the review of titles and abstracts, integrated by scanning the references and consulting experts in the field, yielded 27 relevant articles. Four articles were excluded because they were published as abstracts and/or full text was not available, and the other four were excluded because they were written in languages other than English. Figure 1 presents a flowchart of manuscript selection.

Bottom Line: Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids.To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies.A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration.

View Article: PubMed Central - PubMed

Affiliation: Center for the Evaluation and Research on Pain (CERP), Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

ABSTRACT
Pain is a frequent and important symptom in cancer patients. Among the available strong opioids, transdermal buprenorphine has been licensed in Europe since 2002, and results from a few clinical studies suggest that it may be a good alternative to the other oral or transdermal opioids. To assess the best available evidence on its efficacy and safety, we carried out a systematic literature review with the aim of pooling relevant studies. We identified 19 eligible papers describing 12 clinical studies (6 randomized controlled trials and 6 observational prospective studies), including a total of about 5000 cancer patients. Given the poor quality of reports and the heterogeneity of methods and outcomes, pooling was not feasible as the type of data was not appropriate for combining the results statistically. A meta-analysis based on individual data is ongoing in the context of the Cochrane Collaboration. In conclusion, although the narrative appraisal of each study suggests a positive risk benefit profile, well designed and statistically powered controlled clinical trials are needed to confirm this preliminary evidence.

No MeSH data available.


Related in: MedlinePlus